Save

VIDEO: Older age, more severe IBS linked to relapse after treatment with Xifaxan

ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on . Please provide your email address to receive an email when new articles are posted on Subscribe ADDED TO EMAIL ALERTS You've successfully added to your alerts. You will receive an email when new content is published.



Click Here to Manage Email Alerts You've successfully added to your alerts. You will receive an email when new content is published.



Click Here to Manage Email Alerts



Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.



Back to Healio

CHICAGO — In this exclusive video from Digestive Disease Week, Mark Pimentel, MD, executive director of the Medically Associated Science and Technology program at Cedars Sinai, discusses his research on predicting response to Xifaxan in patients with irritable bowel syndrome.

“We think IBS, in part, is due to changes in the gut microbiome and particularly in the small bowel, and that’s where rifaximin or Xifaxan [Salix Pharmaceuticals] comes in,” he said. “What we learned at this DDW is some more information about who might respond to rifaximin.”

Although the study was large, it was difficult to identify predictors in multivariable analysis, Pimentel noted. However, younger patients were more likely to respond and have a sustained response, and univariate analysis showed more severe IBS was linked to relapsing sooner, he said.

Reference:

Pimentel M, et al. Abstract Tu1619. Presented at: Digestive Disease Week; May 6-9, 2017; Chicago.

Disclosures: Pimentel reports financial relationships with Synthetic Biologics, Salix, Naia Pharmaceuticals, Commonwealth Diagnostics International and Valeant.